RecruitingPhase 2NCT06744647

Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN2030 in Adult Patients With Antibody-Mediated Rejection After Kidney Transplantation

Sponsor

Alexion Pharmaceuticals, Inc.

Enrollment

45 participants

Start Date

Mar 7, 2025

Study Type

INTERVENTIONAL

Conditions

Kidney Transplantation AMR Antibody-mediated Rejection Biopsy-proven Histologic Scores

Summary

The primary objective of this study is to evaluate the efficacy of ALXN2030 compared with placebo on biopsy proven histologic resolution in participants with active or chronic active antibody-mediated rejection (AMR) at Week 52.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called ALXN2030 and a drug called Placebo for people with amr, antibody-mediated rejection, and other related conditions. The study is currently recruiting participants at 55 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGALXN2030

ALXN2030 will be administered subcutaneously (SC).

DRUGPlacebo

Placebo will be administered SC.

Locations(55)

Research Site

Birmingham, Alabama, United States

Research Site

Scottsdale, Arizona, United States

Research Site

Los Angeles, California, United States

Research Site

Orange, California, United States

Research Site

Tampa, Florida, United States

Research Site

Atlanta, Georgia, United States

Research Site

Kansas City, Kansas, United States

Research Site

Ann Arbor, Michigan, United States

Research Site

Detroit, Michigan, United States

Research Site

Livingston, New Jersey, United States

Research Site

New York, New York, United States

Research Site

New York, New York, United States

Research Site

New York, New York, United States

Research Site

New York, New York, United States

Research Site

Durham, North Carolina, United States

Research Site

Cincinnati, Ohio, United States

Research Site

Philadelphia, Pennsylvania, United States

Research Site

Charleston, South Carolina, United States

Research Site

Dallas, Texas, United States

Research Site

Houston, Texas, United States

Research Site

Richmond, Virginia, United States

Research Site

Seattle, Washington, United States

Research Site

Milwaukee, Wisconsin, United States

Research Site

Botucatu, Brazil

Research Site

Campinas, Brazil

Research Site

Porto Alegre, Brazil

Research Site

São Paulo, Brazil

Research Site

São Paulo, Brazil

Research Site

Calgary, Alberta, Canada

Research Site

Edmonton, Alberta, Canada

Research Site

Vancouver, British Columbia, Canada

Research Site

London, Ontario, Canada

Research Site

Toronto, Ontario, Canada

Research Site

Montreal, Quebec, Canada

Research Site

Changsha, China

Research Site

Guangzhou, China

Research Site

Nanning, China

Research Site

Shanghai, China

Research Site

Wuhan, China

Research Site

Xi'an, China

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Barcelona, Spain

Research Site

Barcelona, Spain

Research Site

Zaragoza, Spain

Research Site

Kaohsiung City, Taiwan

Research Site

Kaohsiung City, Taiwan

Research Site

Taichung, Taiwan

Research Site

Taoyuan, Taiwan

Research Site

Birmingham, United Kingdom

Research Site

London, United Kingdom

Research Site

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06744647

Related Trials

Ex Vivo Normothermic Perfusion in Kidney Transplantation.

NCT051758851 location

Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD

NCT072247631 location

Multiparametric MRI in a Prospective Cohort of Living Kidney Donors, Recipients, and Healthy Controls: Correlations With Markers of Renal Function, Fibrosis and Ageing

NCT062105552 locations

Continuous Glucose Monitoring (CGM) After Kidney Transplantation

NCT066759031 location

A Two Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated Rejection (ABMR).

NCT076414264 locations